TARX (Tarsier Pharma) EBITDA Margin %: 0.00% (As of Dec. 2025)


What is Tarsier Pharma EBITDA Margin %?

Tarsier Pharma TARX EBITDA Margin % is 0.00% as of Dec. 2025.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Tarsier Pharma's EBITDA for the six months ended in Dec. 2025 was $-1.31 Mil. Tarsier Pharma's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Tarsier Pharma's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Tarsier Pharma  (NYSE:TARX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Tarsier Pharma EBITDA Margin % Related Terms

Tarsier Pharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Tarsier Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsier Pharma EBITDA Margin % Chart

Tarsier Pharma Annual Data
Trend Dec23 Dec24 Dec25
EBITDA Margin %
0.00 0.00 0.00

Tarsier Pharma Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % 0.00 0.00 0.00 0.00 0.00

TARX vs : EBITDA Margin % Comparison

For the Biotechnology subindustry, Tarsier Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tarsier Pharma EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tarsier Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Tarsier Pharma's EBITDA Margin % falls into.


Tarsier Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Tarsier Pharma's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-2.549/0
= %

Tarsier Pharma's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-1.311/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Tarsier Pharma (TARX) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tarsier Pharma and its competitors.
Is Tarsier Pharma's EBITDA Margin % too high?
Tarsier Pharma's current EBITDA Margin % is 0.00%.
How does Tarsier Pharma's EBITDA Margin % compare to ?
Tarsier Pharma's EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tarsier Pharma and its competitors. Tarsier Pharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsier Pharma stock overvalued right now?
Tarsier Pharma (TARX) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Tarsier Pharma (TARX), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tarsier Pharma Business Description

Comparable Companies
Tarsier Pharma Ltd is a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet needs in ocular diseases with underlying inflammatory pathologies. Its dazdotuftide platform technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops and intravitreal injections. The company's Product Candidate Pipeline includes TRS01 and TRS02.